key: cord-1034161-zqsl3qme authors: Rungsiwiwut, Ruttachuk; Virutamasen, Pramuan; Pruksananonda, Kamthorn title: Mesenchymal stem cells for restoring endometrial function: An infertility perspective date: 2020-07-20 journal: Reprod Med Biol DOI: 10.1002/rmb2.12339 sha: 82509c9187f24d46afcaf22c020044d96caf5c08 doc_id: 1034161 cord_uid: zqsl3qme BACKGROUND: Mesenchymal stem cells (MSCs) can be derived from several tissues such as bone marrow, placenta, adipose tissue, or endometrial tissue. MSCs gain a lot of attention for cell‐based therapy due to their characteristics including differentiation ability and immunomodulatory effect. Preclinical and clinical studies demonstrated that MSCs can be applied to treat female infertility by improving of the functions of ovary and uterus. This mini‐ review focuses on the current study of treatment of endometrial infertility by using MSCs. METHODS: The present study performed a literature review focusing on the effect of MSCs for treatment of women infertility caused by endometrial dysfunction. RESULTS: Bone marrow‐, umbilical cord‐, adipose‐, amniotic‐, and menstruation‐derived MSCs enhance endometrial cell proliferation, injury repairs as well as reducing scar formation. The beneficial mechanism probably via immunomodulatory, cell differentiation, stimulates endometrial cell proliferation and down‐regulation of fibrosis genes. The major advantage of using MSCs is to improve endometrial functions resulting in increased implantation and pregnancy. CONCLUSIONS: MSCs exhibit a potential for endometrial infertility treatment. Adipose‐ and menstruation‐derived stem cells show advantages over other sources because the cells can be derived easily and do not causes graft rejection after autologous transplantation. derived from cord blood and placenta showed some variation according to the donor. 6 Therefore, according to the minimal criteria proposed by the International Society for Cellular Therapy (ISCT) to define human MSCs are including, (a) under the standard culture condition, MSCs must grow adherently to surface of the culture vessels, (b) MSCs exhibit the phenotype similar to those fibroblast cells, (c) MSCs express at least CD73, CD90, and CD105 while lack expression of CD34, CD45, CD14, CD19, and HLA-DR, 7, 8 and (d) MSCs enable to osteogenic-, chondrogenic-, and adipogenic differentiation. 7 Interestingly, MSCs have demonstrated the ability to differentiation into cardiomyocytes, 9 hepatocytes, 10 and pancreatic secreting cells. 11 Despite of the differentiation ability, the immunomodulatory capacity makes MSCs as a candidate cell type for immune therapy. [12] [13] [14] The immunomodulatory mechanism of MSCs involves with migration of MSCs to the area of injury or inflammation, follows by interaction with immune cells resulting in suppression or stimulation of innate and adaptive immune system of the host. 15 In addition, the ability of MSCs to downregulate of MHC class II upon allogeneic transplantation makes MSCs suitable for cell-based therapy without the risk of immune rejection. 16 With the advantage of MSCs, the first MSC drug was developed for immunomodulatory treatment of graftversus-host disease (GVHD). 17 Recently, the researchers in China have demonstrated the beneficial effect of MSCs after treatment of patients suffering from respiratory complication due to infection. 18, 19 COVID-19 patients received intravenous infusions of MSCs and it improves the patient outcomes, indicates that the MSC treatment is safe and promising. Therefore, several studies are focusing on using of MSCs as a high potential source of stem cells for regenerative medicine and immunomodulatory therapy in several diseases including infertility. Human uterus is anatomically divided into three layers including perimetrium, myometrium, and endometrium. Endometrium locates at the innermost area of uterus which can be divided into two sublayers, the basal layer which connects to myometrium and the functional layer which is facing to the cavity of uterus. 20 Endometrium is dynamically regenerated in the response to reproductive hormones. The regeneration of endometrium is influenced by the fluctuation of major hormonal levels including estrogen and progesterone, resulting in menstrual cycle. 21 The menstrual cycle begins with the ovaries produces and releases estrogen. Estrogen stimulates the endometrial cells to proliferate resulting in thicken of the functional layer. During this phase, the vessels and the endometrial glands are increasing their sizes. Later, in the mid of menstrual cycle, the peak of the estrogen level occurs followed by releasing of the oocytes so called ovulation. Following the ovulation, the level of progesterone begins to increase. Increasing of progesterone level activates the function of endometrial layer in order to prepare for implantation of the embryo. However, if the implantation does not occur, the levels of estrogen and progesterone will decline and followed by the shedding of endometrial lining. This shedding of endometrial tissue is recognized as menstruation. The cycle of menstruation is completed by finishing of shedding process and subsequently the new cycle begins. Therefore, regeneration of both functional and basal layers of endometrium importantly involves in menstruation and embryo implantation. The process that the blastocyst embryo interacts with the functional layer of uterus is known as implantation. The process begins with the embryo attaches to the epithelial surface of endometrium, invades the epithelial surface, and proceeds decidualization. In general, successful clinical pregnancy depends on synchronization of blastocyst embryos and endometrial receptivity with optimal decidualization. 22 Decidualization is the process in which the stromal cells of endometrium change their morphology in order to preparing the suitable conditions for embryo implantation. 22 In human, however, decidua is formed routinely in relation to menstruation and shed off if the embryo implantation does not occur. 23 In contrast, in case of fertilization followed by implanting of embryo, the decidua stroma remains cotact. 24 It is generally accepted that decidualization plays a key role in embryo implantation and maintenance of pregnancy. During the process of decidualization, there are cellular and molecular changes occur in the endometrial layer include, increasing of oxidative stress resistance, modulating a local inflammatory response resulting in allowing of trophoblast invasion. In contrast, diminishing of decidualization causes some reproductive problems, such as failure of implantation, miscarriage, and dysfunction of uterus. 25 Interestingly, low implantation rate after transferring of high-quality embryos in infertile patients emphasizes the importance of a diminished decidualization. Therefore, impairment of decidualization is one of a major causes of pregnancy failure and infertility. 26 Infertility often creates problems for the couples, and the women are frequently blamed for the cause of problem. 27 In a larger scale, however, infertility involves in decreasing of birthrate in many country and influences the national policy, especially in the country that is facing aging society. Infertility is clinically defined as a disease of the reproductive system, failure to achieve a clinical pregnancy after 12 months of having regular unprotected sexual intercourse. 28 According to World Health Organization (WHO), infertility can be classified into primary and secondary infertility. Primary infertility is referred to a woman who has never been pregnant and secondary infertility is referred to a woman who has had at least one successful pregnancy but later experiences the incapability to pregnant. 29 Mascarenhas and colleagues (2012) 30 reported that globally, 19.2 million out of 48.5 million of infertile couple suffered from primary infertility and 29.3 million infertile couple were suffered from secondary infertility. Interestingly, primary infertility was a common cause for couple in the developed countries, whereas in developing countries, secondary infertility was found to be a major cause. 30 Despite of the country factor, approximately 25% of infertility has been attributed to male, whereas 58% to female, and 17% to unexplained cause. 31 Focusing on female factor, female infertility may cause by disturbances of reproductive organs or central nervous system that secrets hormones controlling the reproductive system. The abnormalities including anovulation, fallopian tube disease, pelvic adhesions, endometriosis, and unexplained factors are reported as the cause of female infertility. 32 However, it is generally accepted that main factor affecting female fertility is an age. Theoretically, woman is born with limited number of oocytes. Female fertility dramatically declines after the certain age, due to the degeneration rate of follicles in the ovaries, increasing of abnormal mitochondria and chromosomal abnormalities in oocytes as well as increasing the incidence of miscarriage. 33 Treatment of female infertility is still complicated; therefore, novel treatment is needed to be developed and evaluated for safety and efficiency. As mentioned in the previous section, several factors cause female infertility including anovulation, fallopian tube disease, pelvic adhesions, endometriosis, and unexplained infertility. 32 However, this review highlights only infertility that caused by endometrium dysfunction. Fibroids or scaring in the uterine tissue can deform the uterine cavity resulting in difficulty for implantation. The major causes of scarring or adhesion include previous uterine surgery or infection of the endometrium. Intrauterine adhesions (IUAs), also known as Asherman's syndrome, caused fibrous strings connecting inside the uterine wall. Damage of the endometrial layer can lead to scar formation resulting in partially or completely obstructs the uterine cavity. 34 Several abnormalities of the reproductive system including hypomenorrhea, amenorrhea, infertility, and recurrent miscarriages can be found in patients with IUAs. 34 To date, numerous treatments such as hormonal treatment, insertion of an intrauterine device (IUD), or barrier gels can be applied for treatment of IUAs. 34, 35 Interestingly, existing of stem cells in the basal layer of endometrium is probably the key factors for treatment of IUAs by stem cell-based therapy. 36 Endometriosis is a disease with unknown cause, characterized by ectopic endometrial implants throughout the pelvis, and negatively impacts fertility. 37 Some patients that develop minimal to mild endometriosis have an almost normal probability of pregnancy but some experience infertility for unknown reasons. In cases of moderate and severe endometriosis, more scar adhesions occur and interrupt the movement of oocyte to the fallopian tube, causing the reduction of natural conception. As a result, endometriosis may lead to an abnormal implantation resulting in subfertility. 38 Congenital mesonephric anomalies and Mullerian malformation results in uterine abnormalities. Anatomical abnormalities of female reproductive organs including duplication of uterus, cervix and vagina, failure of forming the uterus, and abnormalities of uterine structures cause serious clinical symptoms, affects the quality of life, and creates the fertility problems. 39, 40 Endometrial thickness can be used to predict the endometrial receptivity. 41 Endometrial thickness is clinically defined as the distance between the myometrium and endometrium which can be measured by ultrasonography. 42 Normally, the endometrial thickness shows different ranges according to the uterine cycles. In menstrual phase, the thickness ranges from 1 to 4 mm, mid-proliferative phase ranges from 4 to 8 mm, late follicular phase ranges from 8 to 14 mm, and secretory phase ranges from 7 to 14 mm. 43, 44 Slow proliferation of uterine epithelium and stroma cells can lead to thin endometrium. Several pathological conditions such as Asherman's syndrome, previous intrauterine surgery, pelvic radiation have been reported to be the causes of thin endometrium. 45, 46 Theoretically, thin endometrium can be improved by regeneration of endometrial stromal and epithelial cells resulting in improvement of implantation. 45 Some reports suggested that the endometrium which represents the thickness more than 17 mm is related with improving pregnancy rate. 47, 48 However, it has to be considered that thickened endometrium is associated with fibroid or polyps which have adversely affect the implantation of embryo. 49 In order to solve the infertility caused by thin endometrium, several methods for endometrial preparation have been described. It is still in a premature stage to conclude for the best procedure for improving implantation of thin endometrial patient. Stem cells exhibit unique characteristics of self-renewal and differentiation potential. Recently, cell therapy using stem cells becomes a novel treatment for several diseases including infertility. However, only the uses of MSCs for treatment of endometrial infertility are highlighted in the present review. Bone marrow-derived stem cells (BMSCs) can be differentiated into many cell types such as skeletal myoblasts, hepatic epithelium, neuroectodermal cells, and endometrial cells. 50, 51 BMSCs display immunoregulatory properties. 52 In addition, it has been demonstrated that BMSCs can secrete several growth factors such as hepatocyte growth factor, platelet-derived growth factor, and transforming growth factor-β. 53 Strikingly, some patients established pregnancy without any medical intervention after treatment. Adipose-derived stem cells (ADSCs) can be isolated from adipose tissue. ADSCs have been intensively examined for the therapeutic ef- Human umbilical cord-derived stem cells (hUC-MSCs) can be iso- these results indicate a promising future for IUA patients, but also prove that tissue engineering can be applied with hUC-MSCs in order to increasing their therapeutic efficiency. 72 Human amniotic tissue is a postnatal membrane, normally discarded after delivery. Human MSCs can be isolated from amniotic tissue called human amniotic-derived stem cells (hAMSCs). Interestingly, human amniotic epithelial cells (hAECs) which are the epithelial cells derived from amniotic tissue exhibit multipotential differentiation, immune-regulating potential, and low tumorigenicity similar to hAM-SCs and other type of MSCs. 73 Therefore, hAECs have a potential in cell-based therapy. In an IUA mouse models, Li et al 73 showed that endometrial morphology was improved after transplantation of hAECs. hAECs MSCs have exhibited a great potential for treatment of infertility This study is supported by the grants from Faculty of Medicine, Srinakharinwirot University (MED-RES-200). There are no conflicts of interest to declare. This article was performed without having any human or animal subjects. A novel method to derive amniotic fluid stem cells for therapeutic purposes Successful derivation of xeno-free mesenchymal stem cell lines from endometrium of infertile women In search of "stemness Comparison of molecular profiles of human mesenchymal stem cells derived from bone marrow, umbilical cord blood, placenta and adipose tissue Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement Immunological characteristics of mesenchymal stem cells Cardiomyocyte differentiation of mesenchymal stem cells from bone marrow: new regulators and its implications Enhanced hepatogenic differentiation of human Wharton's jelly-derived mesenchymal stem cells by using three-step protocol An overview on small molecule-induced differentiation of mesenchymal stem cells into beta cells for diabetic therapy Human mesenchymal stem cells modulate allogeneic immune cell responses Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation Mesenchymal stem cells suppress B-cell terminal differentiation Immune modulation by mesenchymal stem cells Mini review: application of human mesenchymal stem cells in gene and stem cells therapy era Mesenchymal stem cell in clinical applications Transplantation of ACE2 -mesenchymal stem cells improves the outcome of patients with COVID-19 Pneumonia Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia Human uterine biopsy: research value and common pitfalls Immunohistochemical labelling of steroid receptors in normal and malignant human endometrium Cyclic decidualization of the human endometrium in reproductive health and failure Endometrial decidualization: of mice and men Fertile ground: human endometrial programming and lessons in health and disease Preconception resveratrol intake against infertility: Friend or foe Decidualization of the human endometrium The social meaning of infertility in south-west Nigeria International Committee for Monitoring Assisted Reproductive Technology (ICMART) and the World Health Organization (WHO) revised glossary of ART terminology Difference between Primary and Secondary Infertility in Morocco: Frequencies and Associated Factors National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys Harrison's Principles of Internal Medicine Ovarian ageing: the role of mitochondria in oocytes and follicles Asherman's syndrome: current perspectives on diagnosis and management Therapeutic effect of human amniotic epithelial cells in rat models of intrauterine adhesions Dissecting fibrosis: therapeutic insights from the small-molecule toolbox Impact of endometriosis on in vitro fertilization outcomes: an evaluation of the Society for Assisted Reproductive Technologies Database The effect of endometriosis on implantation: results from the Yale University in vitro fertilization and embryo transfer program The presentation and management of complex female genital malformations Congenital Uterine Malformation by Experts (CUME): better criteria for distinguishing between normal/arcuate and septate uterus? Endometrial Receptivity and its Predictive Value for IVF/ICSI-Outcome Thin endometrium in assisted reproductive technology Transvaginal sonographic evaluation of endometrial growth and texture in spontaneous ovulatory cycles-a descriptive study Oral contraceptives maintain a very thin endometrium before operative hysteroscopy Pathophysiologic features of 'thin' endometrium Management of thin endometrium in assisted reproduction: a clinical practice guideline from the Canadian Fertility and Andrology Society The correlation between endometrial thickness and outcome of in vitro fertilization and embryo transfer (IVF-ET) outcome Relationship between endometrial thickness and embryo implantation, based on 1,294 cycles of in vitro fertilization with transfer of two blastocyst-stage embryos Fibroids and infertility: an updated systemic review of the evidence Plasticity of bone marrow-derived stem cells Contribution of bone marrow-derived stem cells to endometrium and endometriosis Mesenchymal stem cells: mechanisms of immunomodulation and homing Differentiation of human bone marrow mesenchymal stem cells into bladder cells: potential for urological tissue engineering Adult bone marrow progenitors become decidual cells and contribute to embryo implantation and pregnancy Endometrial cells derived from donor stem cells in bone marrow transplant recipients Bone marrow-derived stem cells contribute to regeneration of the endometrium Phenotypic and functional characterization of mesenchymal stem cells from chorionic villi of human term placenta Bone marrow mesenchymal stem cells (BMSCs) restore functional endometrium in the rat model for severe Asherman syndrome Bone marrow-derived cells or C-X-C motif chemokine 12 (CXCL12) treatment improve thin endometrium in a mouse model Uterine infusion with bone marrow mesenchymal stem cells improves endometrium thickness in a rat model of thin endometrium Application of bone marrow-derived mesenchymal stem cells in the treatment of intrauterine adhesions in rats Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman's syndrome and endometrial atrophy: a pilot cohort study Effect of stem cell application on Asherman syndrome, an experimental rat model Adipose-derived stem cells transplantation improves endometrial injury repair Exosomes derived from adipose mesenchymal stem cells restore function endometrium in a rat model of intrauterine adhesions Application of autologous adipose-derived stem cells for thin endometrium treatment in patients with failed ART programs Using mesenchymal stem cells to treat female infertility: an update on female reproductive diseases Human umbilical cord mesenchymal stem cells and the treatment of spinal cord injury Comparison of proliferative and multilineage differentiation potential of human mesenchymal stem cells derived from umbilical cord and bone marrow Therapeutic effect of human umbilical cord-derived mesenchymal stem cells on injured rat endometrium during its chronic phase Umbilical cord mesenchyme stem cell local intramuscular injection for treatment of uterine niche Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial Human amniotic epithelial cells improve fertility in an intrauterine adhesion mouse model Human amniotic mesenchymal stromal cell transplantation improves endometrial regeneration in rodent models of intrauterine adhesions Spatial and temporal characterization of endometrial mesenchymal stem-like cells activity during the menstrual cycle Biological characteristics of human menstrual blood-derived endometrial stem cells Effects of menstrual blood-derived stem cells on endometrial injury repair Human menstrual blood-derived stem cells promote the repair of impaired endometrial stromal cells by activating the p38 MAPK and AKT signaling pathways PI3K-PKB/Akt pathway Platelet-rich plasma improves therapeutic effects of menstrual blood-derived stromal cells in rat model of intrauterine adhesion Autologous menstrual blood-derived stromal cells transplantation for severe Asherman's syndrome The fate of autologous endometrial mesenchymal stromal cells after application in the healthy equine uterus Amniotic membrane-derived mesenchymal cells and their conditioned media: potential candidates for uterine regenerative therapy in the horse